苯并恶唑胺
苯并恶唑胺 性质
| 熔点 | 181-184 °C(lit.) |
|---|---|
| 沸点 | 316.8±34.0 °C(Predicted) |
| 密度 | 1.4369 (rough estimate) |
| 折射率 | 1.5618 (estimate) |
| 储存条件 | Keep in dark place,Sealed in dry,2-8°C |
| 溶解度 | 可溶于二甲基亚砜、甲醇 |
| 酸度系数(pKa) | 0.73±0.10(Predicted) |
| 形态 | 粉末 |
| 颜色 | 浅棕色至黄棕色 |
| Merck | 13,10249 |
| CAS 数据库 | 61-80-3(CAS DataBase Reference) |
| NIST化学物质信息 | Zoxazolamine(61-80-3) |
苯并恶唑胺 用途与合成方法
Zoxazolamine是中枢性肌肉松弛剂类药物，据报道通过降低中枢神经元间活性发挥作用。这些药物，但不是抗焦虑药，减少多巴胺的转化，并且诱发多巴胺能神经元处类似心脏起搏器样的放电模式。 Zoxazolamine属于具有生物活性的2-氨基-2-恶唑类。 Zoxazolamine也被用来作为评估肝细胞色素P-450活性的一种工具。
Zoxazolamine is widely used for a pharmacologic test that serves as a convenient indicator of changes in cytochrome P-450 activity in rodents. The time-averaged serum clearance determined from tested concentrations data is 7.22±1.01 mL/min/kg for Zoxazolamine. Infusion of Zoxazolamine to righting reflex (LRR) at three different rates shows increasing Zoxazolamine concentration in serum and brain at the onset of the effect with increasing infusion rates. When the Zoxazolamine infusion is continued for 5 min beyond the onset of LRR, the concentrations of Zoxazolamine in the cerebrospinal fluid (CSF) at the offset of LRR are essentially identical to the onset concentrations.
安全信息
| 危险品标志 | Xn |
|---|---|
| 危险类别码 | 20/21/22-36/37/38 |
| 安全说明 | 26-36 |
| WGK Germany | 3 |
| RTECS号 | DM4550000 |
| 海关编码 | 29349990 |
| 毒性 | LD50 in mice, rats (mg/kg): 376, 102 i.p.; 678, 730 orally (Cain, Roszkowski) |
苯并恶唑胺 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2024-08-19 | 10338 | 2-氨基-5-氯苯并恶唑 | 61-80-3 | 1g | 364 |
| 2024-08-19 | 10338 | 2-氨基-5-氯苯并恶唑 | 61-80-3 | 5g | 1021 |
